<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002917'>Hypomagnesemia</z:hpo> is common in hospitalized patients, especiaLLy in the eLderLy with <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (CAD) and/or those with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0002917'>Hypomagnesemia</z:hpo> is associated with the risk of <z:hpo ids='HP_0000822'>hypertension</z:hpo>, type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, increased mortality from <z:hpo ids='HP_0000001'>all</z:hpo> cause and CAD </plain></SENT>
<SENT sid="2" pm="."><plain>Higher <z:chebi fb="131" ids="25107">magnesium</z:chebi> intake, however, has been associated with a Lower risk of developing <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, a problem which exists in 25% of American adults </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="131" ids="25107">Magnesium</z:chebi> supplementation improves myocardial metabolism, inhibits calcium accumulation and myocardial cell <z:hpo ids='HP_0011420'>death</z:hpo>; it improves vascular tone, peripheral vascular resistance, afterload and cardiac output, reduces <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> and improves <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="131" ids="25107">Magnesium</z:chebi> also reduces vulnerability to oxygen-derived free radicals, improves human endothelial function and inhibits platelet function, including platelet aggregation and <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, which potentially provides <z:chebi fb="131" ids="25107">magnesium</z:chebi> with physiologic and natural effects similar to <z:chebi fb="3" ids="16335">adenosine</z:chebi>-<z:chebi fb="2" ids="18361">diphosphate</z:chebi> inhibitors, such as <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Data on <z:chebi fb="131" ids="25107">magnesium</z:chebi> supplementation in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e>) are conflicting </plain></SENT>
<SENT sid="6" pm="."><plain>ALthough a number of relatively small randomized cLinicaL trials have demonstrated a remarkable reduction in mortality when <z:chebi fb="131" ids="25107">magnesium</z:chebi> is administered to relativeLy high risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> patients, two recently published large-scale randomized cLinical trials (the Fourth International Study of <z:mpath ids='MPATH_124'>Infarct</z:mpath> Survival and <z:chebi fb="131" ids="25107">Magnesium</z:chebi> in Coronaries) failed to show any superiority of intravenous <z:chebi fb="131" ids="25107">magnesium</z:chebi> over placebo </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, the theoretical potential benefits of <z:chebi fb="131" ids="25107">magnesium</z:chebi> supplementation as a cardioprotective agent in CAD patients, its relatively low cost, easy administration, and relatively insignificant adverse effects, gives <z:chebi fb="131" ids="25107">magnesium</z:chebi> a place in treating CAD patients, especially those at high-risk and in life-threatening <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>, such as Torsades de Points and intractable <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> </plain></SENT>
</text></document>